After lining up an application for FDA approval of a new approach to treating fluid retention in heart failure patients a few months ago, Burlington, MA-based scPharmaceuticals is shooting for a $100 million IPO.
The biotech has developed a new formulation of furosemide so it could be delivered via a wearable device, rather than delivered through an IV in the hospital. The combo has the simple intention of reducing the number of days a patient has to be hospitalized for therapy — in a heart failure market that accounts for millions of patients — and the biotech has plans for more IV-replacement programs much like it.
The first NDA was field in August, according to the S-1.
Next in line are two antibiotics: scCeftriaxone, an antibiotic currently used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. And there’s another program for scCarbapenem.
The venture backed biotech had burned through close to $55 million through the end of last June.
Here are the venture groups with the biggest stakes in this biotech’s future: 5AM Ventures, which owns 23.2% of the company, Lundbeckfond, 22.6%, OrbiMed, 23% and Sun Pharmaceutical, 16%.
Biotech IPOs are going and blowing in Q4, offering a shot at some major financing events for drug and device makers.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,200+ biopharma pros who read Endpoints News by email every day.Free Subscription